Page last updated: 2024-10-15

s 8932

FloraRankFlora DefinitionFamilyFamily Definition
Panelgenus[no description available]CombretaceaeA plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. They are mostly trees and shrubs growing in warm areas.[MeSH]

Cross-References

ID SourceID
PubMed CID121304016
CHEMBL ID4065616
CHEBI ID145994
SCHEMBL ID17712225
MeSH IDM0223241

Synonyms (59)

Synonym
gs-5734 ,
2-ethylbutyl (2s)-2-{[(s)-{[(2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate
gs 5734
2-ethylbutyl n-[(s)-{[(2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]-l-alaninate
(2s)-2-{(2r,3s,4r,5r)-[5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]phenoxy-(s)-phosphorylamino}propionic acid 2-ethyl-butyl ester
remdesivir ,
1809249-37-3
remdesivirum
CHEBI:145994 ,
gs5734
S8932
veklury
2-ethylbutyl (2s)-2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
2-ethylbutyl (2s)-2-(((2r, 3s, 4r, 5r)-5-(4-aminopyrrolo(2,1-f) (1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl) methoxy)(phenoxy) phosphoryl) amino) propanoate
3qki37eehe ,
l-alanine, n-((s)-hydroxyphenoxyphosphinyl)-, 2-ethylbutyl ester, 6-ester with 2-c-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-d-altrononitrile
remdesivir [usan]
unii-3qki37eehe
AC-31297
SCHEMBL17712225
AT11308
remdesivir [jan]
2-ethylbutyl n-((s)-(2-c-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-2,5-anhydro-d-altrononitril-6-o-yl)phenoxyphosphoryl)-l-alaninate
remdesivir [who-dd]
remdesivir [orange book]
CS-0028115
HY-104077
RWWYLEGWBNMMLJ-YSOARWBDSA-N
(s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
AKOS032946252
2-ethylbutyl (2s)-2-{[(s)-{[(2r,3s,4r,5r)-5-{4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl}-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate
DB14761
DT-0049
BCP24975-1
(s)-2-ethylbutyl 2-((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate
D11472
remdesivir (jan/usan)
veklury (tn)
NCGC00686694-01
CHEMBL4065616
bdbm429505
med.21724, compound 178
2-ethylbutyl (2s)-2-[[[(2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
compound 4b [pmid: 28124907]
gtpl10715
EX-A3265
remdesivir (gs-5734)
nsc-825151
nsc825151
l-alanine, n-[(s)-hydroxyphenoxyphosphinyl]-, 2-ethylbutyl ester, 6-ester with 2-c-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-d-altrononitrile; 2-ethylbutyl ((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydrox
mfcd31657351
DTXSID701022537
c27h35n6o8p
2-ethylbutyl (2s)-2-[[(s)-[[(2r,3s,4r,5r)-5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy]phenoxyphosphoryl]amino]propanoate
HB9521
EN300-22849306
sars-cov-2 antiviral agents: remdesivir
compound 4b (pmid: 28124907)
(2s)-2-((2r,3s,4r,5r)-(5-(4-aminopyrrolo(2,1-f)(1,2,4)triazin-7-yl)-5-cyano-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy)phenoxy-(s)-phosphorylamino)propionic acid 2-ethyl-butyl ester

Toxicity

ExcerptReference
" All adverse events were grade 1 or 2 in severity."( Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID-19, in Healthy Subjects.
Cao, H; Chng, E; German, P; Humeniuk, R; Ling, J; Mathias, A; Osinusi, A; Shen, G; Vu, A, 2020
)
"To find effective and safe treatments for COVID-19, the WHO recommended to systemically evaluate experimental therapeutics in collaborative randomised clinical trials."( Protocol for the DisCoVeRy trial: multicentre, adaptive, randomised trial of the safety and efficacy of treatments for COVID-19 in hospitalised adults.
Ader, F, 2020
)
" Remdesivir reduced serious adverse effects by absolute 6% and no significant Grade 3 or 4 adverse effects were reported."( Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis.
Abdallah, MS; Elsawah, HK; ElShafie, AH; Elsokary, MA, 2021
)
" The most common adverse reaction was hepatic impairment, although the trials reported a similar proportion of adverse events in the intervention and control groups."( Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in management of COVID-19: A scoping review.
Andersson, N; Cockcroft, A; Laurie, C; Pimentel, J, 2021
)
" Trial data report a similar proportion of adverse events in treated and control groups."( Clinical studies assessing the efficacy, effectiveness and safety of remdesivir in management of COVID-19: A scoping review.
Andersson, N; Cockcroft, A; Laurie, C; Pimentel, J, 2021
)
" Harms are typically assessed through the collection of adverse events (AEs)."( Advantages of visualisations to evaluate and communicate adverse event information in randomised controlled trials.
Cornelius, V; Cro, S; Phillips, R, 2020
)
" The outcomes of interest were mortality, progression to severe disease (severe pneumonia, admission to intensive care unit (ICU), and/or mechanical ventilation), viral clearance rate, QT prolongation, fatal cardiac complications, and noncardiac serious adverse events."( Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.
An, MH; Hwang, TH; Kim, MS; Kim, WJ, 2020
)
"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic posed a serious public health concern and started a race against time for researchers to discover an effective and safe therapy for coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2."( The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.
Abou-Sleymane, G; Al Faraj, A; Badro, DA; Daou, F; Khanafer, N; Tobaiqy, M, 2021
)
" The scientific community is studying and testing numerous compounds that can be effective and safe for treating people with covid-19."( [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]
Amato, L; Cruciani, F; Davoli, M; De Crescenzo, F; Mitrova, Z; Saulle, R; Vecchi, S, 2021
)
" No differences for the risk of any adverse events are observed between convalescent plasma and remdesivir compared to standard treatment."( [The praise of uncertainty: a systematic living review to evaluate the efficacy and safety of drug treatments for patients with covid-19.]
Amato, L; Cruciani, F; Davoli, M; De Crescenzo, F; Mitrova, Z; Saulle, R; Vecchi, S, 2021
)
" Furthermore, no significant association was observed between remdesivir treatment and an increased risk of adverse events."( Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials.
Chen, CH; Chen, KH; Hsueh, PR; Lai, CC; Wang, CY; Wang, YH, 2021
)
" No liver function derangements or any other major adverse events with the drug were reported."( Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation.
Banerjee, S; Chauhan, S; Desai, S; Kute, VB; Meshram, HS; Mishra, V; Navadiya, V; Patel, H; Rizvi, SJ, 2021
)
"RDV therapy is safe and clinically feasible in renal transplant recipients as seen in our cohort."( Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation.
Banerjee, S; Chauhan, S; Desai, S; Kute, VB; Meshram, HS; Mishra, V; Navadiya, V; Patel, H; Rizvi, SJ, 2021
)
" To exclude toxic concentrations of potential drugs, the network was expanded to include a toxic score (TOX) that detected cell death (CPETOXnet)."( Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2.
Bhatia, S; Borkhardt, A; Kather, JN; Kronberg, RM; Lang, KS; Lang, PA; Müller, L; Ostermann, PN; Pandyra, AA; Schaal, H; Stachura, P; Werner, J, 2021
)
" The outcomes studied were mortality, all adverse events, serious adverse events, and clinical improvement."( Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Goudarzi, R; Mehrolhassani, MH; Tasavon Gholamhoseini, M; Yazdi-Feyzabadi, V, 2021
)
"Remdesivir has positive effects on clinical improvement, and reduction of the risk of serious adverse events."( Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
Goudarzi, R; Mehrolhassani, MH; Tasavon Gholamhoseini, M; Yazdi-Feyzabadi, V, 2021
)
"Primary outcome was mortality and secondary outcomes were time to clinical improvement and safety outcomes like serious adverse events, respiratory failure."( Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis.
Chugh, A; Chugh, VK; Khera, D; Khera, PS; Singh, S, 2021
)
" Significant decrease was found in the risk of serious adverse events (RR=0."( Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis.
Chugh, A; Chugh, VK; Khera, D; Khera, PS; Singh, S, 2021
)
" The Adverse events [AEs], Serious adverse events [SAEs] and Treatment Discontinuation due to Adverse Events (TDAE) were used as primary outcome measures."( A Meta-Analysis of Safety of Different Regimens of Remdesivir in COVID-19 Patients.
Bose, D; Konwar, M; Maurya, M, 2022
)
" Serious adverse effects (SAEs) were significantly less common in patients treated with remdesivir, with an absolute risk difference of 6% (RD -0."( Efficacy and safety of remdesivir in hospitalised COVID-19 patients: a systematic review and meta-analysis.
Angamo, MT; Mohammed, MA; Peterson, GM, 2022
)
" The frequencies of serious adverse events (110 [15%] of 750 in the baricitinib group vs 135 [18%] of 752 in the placebo group), serious infections (64 [9%] vs 74 [10%]), and venous thromboembolic events (20 [3%] vs 19 [3%]) were similar between the two groups."( Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Adams, DH; Alatorre-Alexander, J; Cardoso, A; Chakladar, S; Crowe, B; de Bono, S; de Cassia Pellegrini, R; Ely, EW; Estrada, V; Goldman, JD; Kartman, CE; Krishnan, V; Liao, R; Marconi, VC; Piruzeli, MLB; Ramanan, AV; Reis, P; Som, M; Zhang, X, 2021
)
" We aimed to characterize the CV adverse drug reactions (ADRs) associated with remdesivir using VigiBase, an individual case safety report database of the World Health Organization (WHO)."( Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database.
Abou Ghayda, R; Ban, K; Cargnin, S; Choi, JY; Choi, SW; Chung, SK; Dragioti, E; Go, YY; Hong, SH; Jacob, L; Jung, JW; Jung, SY; Kim, AY; Kim, MS; Kim, NK; Kostev, K; Koyanagi, A; Kronbichler, A; Lee, KH; Lee, SW; Li, H; Moon, SH; Park, SJ; Salem, JE; Shin, JI; Shin, JS; Smith, L; Solmi, M; Terrazzino, S; Tizaoui, K; Yon, DK, 2022
)
" We evaluated the safety of remdesivir by examining the incidence of discontinuation of remdesivir treatment because of adverse events and the incidence of any adverse events."( Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19).
Esaka, N; Fujita, K; Hata, H; Kanai, O; Mio, T; Nanba, K; Odagaki, T; Seta, K; Yasoda, A, 2021
)
" Discontinuation of remdesivir because of adverse events occurred in one older patient (3."( Safety of Remdesivir for Patients 80 Years of Age or Older with Coronavirus Disease 2019 (COVID-19).
Esaka, N; Fujita, K; Hata, H; Kanai, O; Mio, T; Nanba, K; Odagaki, T; Seta, K; Yasoda, A, 2021
)
"Although remdesivir (GS-5734) has recently demonstrated clinical benefits against the pandemic outbreak of coronavirus disease 2019 (COVID-19), neuropsychological adverse reactions (ADRs) remain to be examined in real-world settings."( Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
Dragioti, E; Jacob, L; Jung, SY; Kang, HC; Kim, JH; Kim, MS; Kostev, K; Koyanagi, A; Lascu, A; Lee, S; Lee, SW; Salem, JE; Shin, JI; Smith, L; Tizaoui, K; Yang, JW; Yon, DK, 2021
)
"Our study demonstrates that remdesivir, a novel drug applied to the treatment of COVID-19, does not have a significant association with adverse neurologic or psychiatric reactions in the real-world setting."( Neuropsychological adverse drug reactions of Remdesivir: analysis using VigiBase, the WHO global database of individual case safety reports.
Dragioti, E; Jacob, L; Jung, SY; Kang, HC; Kim, JH; Kim, MS; Kostev, K; Koyanagi, A; Lascu, A; Lee, S; Lee, SW; Salem, JE; Shin, JI; Smith, L; Tizaoui, K; Yang, JW; Yon, DK, 2021
)
" Remdesivir was overall well tolerated, and total 119 adverse events were reported; most common were nausea and vomiting in 45."( Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database.
Gogtay, J; Gupte, V; Hegde, R; Jadhav, S; Kalathingal, K; Malabade, R; Sawant, S, 2022
)
"To summarise specific adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir in patients with COVID-19."( Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
Agoritsas, T; Bartoszko, JJ; Brignardello-Petersen, R; Chu, DK; Ge, L; Izcovich, A; Khamis, AM; Kum, E; McLeod, SL; Mustafa, RA; Qasim, A; Rochwerg, B; Siemieniuk, RA; Vandvik, P; Zeraatkar, D, 2022
)
" For most interventions and outcomes the certainty of the evidence was very low to low except for gastrointestinal adverse effects from hydroxychloroquine, which was moderate certainty."( Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials.
Agoritsas, T; Bartoszko, JJ; Brignardello-Petersen, R; Chu, DK; Ge, L; Izcovich, A; Khamis, AM; Kum, E; McLeod, SL; Mustafa, RA; Qasim, A; Rochwerg, B; Siemieniuk, RA; Vandvik, P; Zeraatkar, D, 2022
)
"We aimed to assess longitudinal changes in clinical indexes of corona disease 2019 (Covid-19) patients with mild pulmonary infection during 5 days of remdesivir therapy and determine the effect of age and gender on remdesivir adverse effects (AE)."( Linear mixed model analysis to evaluate correlations between remdesivir adverse effects with age and gender of patients with mild Covid-19 pneumonia.
Amanollahi, A; Basir Ghafouri, H; Hoseini, SE; Moradi Moghaddam, O; Sedighi, M; Tavakoli, N, 2022
)
" All patients recovered without any sequelae, and no serious adverse events were reported."( Safety of Remdesivir in 20 Children with COVID-19-Case Series-
Jinda, T; Kasai, M; Manabe, S; Mizuno, S, 2022
)
"To investigate the signal of disproportionate reporting of remdesivir-related AKI in COVID-19 patients over time with data from US Food and Drug Administration Adverse Event Reporting System."( Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System.
Gaggl, M; Gou, Z; Kinlaw, AC; Li, X; Wang, T; Wei, J; Xu, Y; Zhou, L, 2023
)
" Initial concerns have been raised about the adverse renal and cardiac events associated with remdesivir."( Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Chyou, TY; Nishtala, PS; Orogun, L, 2023
)
"This study aimed to analyse the adverse renal and cardiac events associated with remdesivir in patients with COVID-19 infections using the US FDA adverse event reporting system."( Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Chyou, TY; Nishtala, PS; Orogun, L, 2023
)
"A case/non-case method was used to determine adverse drug events associated with remdesivir as the primary suspect drug between January 1, 2020, and November 11, 2021, for patients with COVID-19 infections."( Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Chyou, TY; Nishtala, PS; Orogun, L, 2023
)
"In the main analysis for remdesivir use in patients with COVID-19 infections, we identified 315 adverse cardiac events comprising 31 different MeDRA PTs and 844 adverse renal events comprising 13 different MeDRA PTs."( Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Chyou, TY; Nishtala, PS; Orogun, L, 2023
)
" Results The frequency of high-grade adverse events was low, except for hyperglycemia (n=59, 45."( Safety and Efficacy of Combination Therapy of Remdesivir, Baricitinib, and High-dose Steroids in Patients Hospitalized with Moderate to Severe COVID-19.
Baba, T; Hagiwara, E; Kaneko, T; Komatsu, S; Nagasawa, R; Niwa, T; Oda, T; Ogura, T; Okuda, R; Yamada, S, 2023
)
" The most common adverse events included nausea, dizziness, and cough."( Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants.
Anoshchenko, O; Chen, S; Davies, S; DeZure, A; Dresser, M; Ellis, S; Girish, S; Humeniuk, R; Johnston, M; Juneja, K; Llewellyn, J; Osinusi, A; Palaparthy, R; Share, A; Winter, H; Xiao, D, 2023
)
"Remdesivir is an antiviral agent, which was shown to be safe and effective in treating early COVID-19, but its favourable impact in hospitalised patients with non-critical disease is still under investigation."( Effectiveness and Safety of Remdesivir in Treating Hospitalised Patients with COVID-19: A Propensity Score Analysis of Real-Life Data from a Monocentric Observational Study in Times of Health Emergency.
Adinolfi, A; Bernasconi, DP; Bertuzzi, M; Colombo, F; Del Gaudio, F; Dicuonzo, A; Epis, OM; Giannattasio, C; Maloberti, A; Rossetti, C; Scaglione, F; Tarsia, P; Travi, G; Ughi, N; Valsecchi, MG, 2023
)
"5%) patients stopped the treatment due to adverse reactions."( Effectiveness and Safety of Remdesivir in Treating Hospitalised Patients with COVID-19: A Propensity Score Analysis of Real-Life Data from a Monocentric Observational Study in Times of Health Emergency.
Adinolfi, A; Bernasconi, DP; Bertuzzi, M; Colombo, F; Del Gaudio, F; Dicuonzo, A; Epis, OM; Giannattasio, C; Maloberti, A; Rossetti, C; Scaglione, F; Tarsia, P; Travi, G; Ughi, N; Valsecchi, MG, 2023
)

Pharmacokinetics

ExcerptReference
" Physiologically based pharmacokinetic modeling was used to inform pediatric dosing for hydroxychloroquine."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
"For hydroxychloroquine, the physiologically based pharmacokinetic model analysis included 500 and 600 simulated white adult and pediatric participants, respectively, and supported weight-normalized dosing for children weighing less than 50 kg."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
"We report the first pharmacokinetic evaluation of remdesivir and GS-441524 in recovered COVID-19 patients."( Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19.
Agrati, C; Ascoli Bartoli, T; Avataneo, V; Capobianchi, MR; Caputi, P; Castilletti, C; D'Avolio, A; Forini, O; Ippolito, G; Lalle, E; Marchioni, L; Nicastri, E; Notari, S; Scorzolini, L; Tempestilli, M, 2020
)
" Because measurement of such concentrations is unrealistic in patients, a physiologically-based pharmacokinetic (PBPK) model was developed to characterize RDV and TN disposition."( Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2.
Gallo, JM, 2021
)
" This report summarizes development of a remdesivir physiologically-based pharmacokinetic (PBPK) model that accurately describes observed adult remdesivir and metabolites exposure and predicts pediatric remdesivir and metabolites exposure."( Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19.
German, P; Kirby, BJ; Lutz, JD; Mathias, A; Pikora, C; Reddy, S, 2021
)
" In spite of United States Food and Drug Administration's recent assent of remdesivir as the only approved agent for COVID-19, there is limited information available about the physicochemical, metabolism, transport, pharmacokinetic (PK), and drug-drug interaction (DDI) properties of this drug."( Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
Deb, S; Reeves, AA, 2021
)
" Physiologically based pharmacokinetic (PBPK) modeling of GastroPlus was used to simulate different patient populations based on age, weight, liver function, and renal function status."( Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
Deb, S; Reeves, AA, 2021
)
"7%, respectively) in mice, which provided good insight into the pharmacokinetic optimization of GS-441524."( Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2.
Aisa, HA; Hu, T; Shen, J; Wei, D; Xie, Y; Xue, H; Zhang, Y; Zheng, W, 2021
)
"This is an open-label, randomized, fixed sequence single intravenous dosing study to assess pharmacokinetic interactions between remdesivir and TDF/3TC (Study A, crossover design) or TDF/3TC plus ATV/r (Study B)."( An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI, 2021
)
" Furthermore, this study will deliver pharmacokinetic datasets for remdesivir drug concentrations and demographic characteristics which could support pharmacometric approaches for simulation of remdesivir treatment regimens in patients concurrently using tenofovir/lamivudine and/or atazanavir/ritonavir."( An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI, 2021
)
" A prospective observational pharmacokinetic study was performed in non-critically ill hospitalized COVID-19 patients with hypoxemia."( Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
Bosma, LBE; Leegwater, E; Moes, DJAR; Ottens, TH; van der Meer, IM; van Nieuwkoop, C; Wilms, EB, 2022
)
"To study the pharmacokinetic inter-individual variability of remdesivir and its main metabolite GS-441524 in a real-world setting of COVID-19 inpatients and to identify possible associations with different demographic/biochemical variables."( Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.
Agrati, C; Ascoli Bartoli, T; Benvenuto, D; Marchioni, L; Nicastri, E; Stazi, GV; Tempestilli, M, 2022
)
" Linear regression, logistic regression and multiple linear regression tests were used for statistical comparisons of pharmacokinetic parameters and variables."( Interpatient variability in the pharmacokinetics of remdesivir and its main metabolite GS-441524 in treated COVID-19 subjects.
Agrati, C; Ascoli Bartoli, T; Benvenuto, D; Marchioni, L; Nicastri, E; Stazi, GV; Tempestilli, M, 2022
)
" Yet, its pharmacokinetic properties are inadequately understood."( A population pharmacokinetic model of remdesivir and its major metabolites based on published mean values from healthy subjects.
Abouellil, A; Bilal, M; Fuhr, U; Taubert, M, 2023
)
" Limited RDV pharmacokinetic (PK) and safety data are available for pregnant women receiving RDV."( Physiologically-based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID-19.
Best, BM; Brooks, K; Capparelli, EV; Clarke, DF; Dallmann, A; Liu, XI; Mirochnick, M; Momper, JD; van den Anker, JN, 2023
)

Compound-Compound Interactions

ExcerptReference
"Management of drug-drug interactions between investigational anti-SARS-CoV-2 drugs and immunosuppressants is a complex task for the clinician."( Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.
Bergan, S; Elens, L; Hesselink, DA; Langman, LJ; Lemaitre, F; Moes, DJAR; Molinaro, M; Venkataramanan, R, 2020
)
" The author here is proposing to test 5-FU in combination with a number of deoxynucleosides on animal models infected with this Covid-19."( 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection.
Ahmad, SI, 2020
)
" We aimed at determining which drugs used in dentistry interact with Remdesivir in order to avoid adverse reactions that may worsen the condition of patients with COVID-19."( Remdesivir-COVID-19: drug interactions in dentistry.
Gómez-Moreno, G, 2020
)
"According to the articles reviewed, a total of 279 drugs interact with Remdesivir."( Remdesivir-COVID-19: drug interactions in dentistry.
Gómez-Moreno, G, 2020
)
" However, management of acute seizures in patients with COVID-19 as well as management of PWE and COVID-19 needs to consider potential drug-drug interactions between antiseizure drugs and candidate drugs currently assessed as therapeutic options for COVID-19."( Management of COVID-19 in patients with seizures: Mechanisms of action of potential COVID-19 drug treatments and consideration for potential drug-drug interactions with anti-seizure medications.
Chandra, PP; Jain, S; Potschka, H; Tripathi, M; Vohora, D, 2021
)
" In spite of United States Food and Drug Administration's recent assent of remdesivir as the only approved agent for COVID-19, there is limited information available about the physicochemical, metabolism, transport, pharmacokinetic (PK), and drug-drug interaction (DDI) properties of this drug."( Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
Deb, S; Reeves, AA, 2021
)
" Subsequently, these data were used in the Drug-Drug Interaction module to simulate drug interaction potential of remdesivir with other COVID-19 drug regimens and with agents used for comorbidities."( Simulation of Remdesivir Pharmacokinetics and Its Drug Interactions.
Deb, S; Reeves, AA, 2021
)
" We discuss the case of a hospitalized patient in the United States diagnosed with COVID-19 pneumonia who developed acute pain crisis secondary to a drug-drug interaction between tramadol and remdesivir, and we propose a possible mechanism of interaction."( Acute Pain Crisis Caused by Tramadol Remdesivir Drug-Drug Interaction.
Feely, M; Ho, I; Miller, G; Teoli, D; Thompson, V; Vlaminck, B; Wright, J, 2021
)
" Given that drug synergy often occurs through inhibition of discrete biological targets, here we propose a neural network architecture that jointly learns drug-target interaction and drug-drug synergy."( Deep learning identifies synergistic drug combinations for treating COVID-19.
Barzilay, R; Collins, JJ; Eastman, RT; Itkin, Z; Jaakkola, TS; Jin, W; Stokes, JM; Zakharov, AV, 2021
)
"In this study, the therapeutic efficacy of quercetin in combination with remdesivir and favipiravir, were evaluated in severe hospitalized COVID-19 patients."( The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial.
Abolnezhadian, F; Alavi, SM; Ghafourian, M; Khodadadi, A; Mahmoudian-Sani, MR; Nashibi, R; Sharhani, A; Shohan, M, 2022
)
" This case report indicated that remdesivir might interact with cytochrome P450 3A4 substrates, such as tacrolimus and everolimus, and elevate their blood concentrations under high inflammatory conditions."( Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient.
Hirai, T; Inoue, T; Iwamoto, T; Mizuta, A; Nishikawa, K; Sasaki, T, 2022
)
" In addition, this case used amiodarone (AMD), and it has been reported that the RDV concentration increases when used in combination with AMD."( [Significant Prolongation of the International Normalized Ratio Associated with COVID-19 Treatment: Possible Drug Interaction with Remdesivir].
Bando, Y; Ishii, H; Otori, K; Yokota, N, 2022
)
" This systematic review aims to evaluate the clinical efficacy and risk of remdesivir alone and in combination with other drugs."( The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis.
Chen, C; Chen, S; Fang, J; Li, X; Rajaofera, MJN; Wang, B; Xia, Q, 2023
)
" Compared with remdesivir alone, remdesivir combined with other drugs (e."( The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis.
Chen, C; Chen, S; Fang, J; Li, X; Rajaofera, MJN; Wang, B; Xia, Q, 2023
)

Bioavailability

ExcerptReference
" Potent orally bioavailable antiviral drugs for early treatment of SARS-CoV-2 infection are urgently needed, and several, including molnupiravir and PF-07321332, are currently in clinical development."( Rethinking Remdesivir: Synthesis, Antiviral Activity, and Pharmacokinetics of Oral Lipid Prodrugs.
Beadle, JR; Carlin, AF; Clark, AE; Garretson, AF; Hostetler, KY; Leibel, SL; McMillan, RE; McVicar, RN; Murphy, J; Schooley, RT; Smith, VI; Valiaeva, N; Xie, J; Zhang, XQ, 2021
)
" However, this nucleoside has a poor oral bioavailability in non-human primates, which may affect its therapeutic efficacy."( Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2.
Aisa, HA; Hu, T; Shen, J; Wei, D; Xie, Y; Xue, H; Zhang, Y; Zheng, W, 2021
)
" Here, we demonstrate the in vitro antiviral activity and in vivo therapeutic efficacy of GS-621763, an orally bioavailable prodrug of GS-441524, the parent nucleoside of remdesivir, which targets the highly conserved virus RNA-dependent RNA polymerase."( Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice.
Babusis, D; Bannister, R; Baric, RS; Barrett, KT; Bilello, JP; Bleier, BJ; Brown, AJ; Chun, K; Cihlar, T; Conrad, WS; Dong, S; Du Pont, V; Feng, JY; Gully, KL; Kalla, R; Mackman, RL; Martinez, DR; May, SR; Meganck, RM; Montgomery, SA; Moreira, FR; Murakami, E; Schäfer, A; Sheahan, TP; Subramanian, R; Tang, J; Won, JJ; Zweigart, MR, 2022
)
" These improvements resulted in a 211% increase in the bioavailability of RDS."( Antiviral Lipid Nanocarrier Loaded with Remdesivir Effective Against SARS-CoV-2 in vitro Model.
Cho, CW; Han, SC; Hwang, D; Hwang, JH; Jeon, WJ; Jung, E; Jung, M; Lee, HK; Na, YG; Shin, JS, 2023
)
" We previously described the synthesis of 1-O-octadecyl-2-O-benzyl-glycero-3-phospho-RVn (V2043), an orally bioavailable lipid prodrug of remdesivir nucleoside (RVn, GS-441524) with broad spectrum antiviral activity against viruses with pandemic potential."( Enhanced broad spectrum in vitro antiviral efficacy of 3-F-4-MeO-Bn, 3-CN, and 4-CN derivatives of lipid remdesivir nucleoside monophosphate prodrugs.
Beadle, JR; Carlin, AF; Clark, AE; Freshman, JE; Garretson, AF; Hostetler, KY; Lo, MK; McMillan, RE; Montgomery, JM; Murphy, J; Schooley, RT; Spiropoulou, CF; Valiaeva, N; Zhang, XQ, 2023
)

Dosage Studied

ExcerptReference
" Effective rabies antivirals for therapeutic use need to be molecules that can be dosed into the cerebrospinal fluid and that rapidly and potently block ongoing virus replication and as such stop the further spread of the virus."( The path towards effective antivirals against rabies.
Jochmans, D; Neyts, J, 2019
)
"Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error)."( Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Ahmed, S; Asperges, E; Bernett, J; Brainard, DM; Cao, H; Castagna, A; Chelliah, D; Chen, D; Chihara, S; Childs, R; Chokkalingam, A; Cohen, SH; Cunningham, J; D'Arminio Monforte, A; Desai, P; DeZure, A; Diaz, G; Elboudwarej, E; Feldt, T; Flanigan, T; Gaggar, A; Green, G; Green, ML; Grein, J; Henne, I; Ismail, S; Kato, H; L'Her, E; Lapadula, G; Lescure, FX; Maeno, T; Majumder, S; Massari, M; Mera, R; Mora-Rillo, M; Mutoh, Y; Myers, RP; Nguyen, D; Nicastri, E; Oda, R; Ohmagari, N; Osinusi, AO; Quiros-Roldan, E; Redinski, J; Sellers, S; Shin, D; Studemeister, A; Tan, SK; Telep, L; Timbs, L; Verweij, E; Winterbourne, L; Yo, K; Zhao, Y; Zhong, L; Zoufaly, A, 2020
)
" To support pediatric clinical studies for investigational treatments of coronavirus disease 2019 (COVID-19), pediatric-specific dosing is required."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
"To define pediatric-specific dosing regimens for hydroxychloroquine and remdesivir for COVID-19 treatment."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
" Physiologically based pharmacokinetic modeling was used to inform pediatric dosing for hydroxychloroquine."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
" A simulation-based dose-ranging study was conducted in simulated children exploring different absolute and weight-normalized dosing strategies."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
"For hydroxychloroquine, the physiologically based pharmacokinetic model analysis included 500 and 600 simulated white adult and pediatric participants, respectively, and supported weight-normalized dosing for children weighing less than 50 kg."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
"This analysis provides pediatric-specific dosing suggestions for hydroxychloroquine and remdesivir and raises concerns regarding hydroxychloroquine use for COVID-19 treatment because concentrations were less than those needed to mediate an antiviral effect."( Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
Balevic, SJ; Benjamin, DK; Cohen-Wolkowiez, M; Gonzalez, D; Hornik, CD; Hornik, CP; Maharaj, AR; Smith, PB; Wu, H; Zimmerman, KO, 2020
)
" Remdesivir was dosed intravenously at 200 mg on day 1 followed by 100 mg/d."( Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Ahn, MY; Arribas López, JR; Bernasconi, E; Bhagani, S; Blair, C; Brainard, DM; Cao, H; Castagna, A; Cattelan, AM; Chai, LYA; Chang, SC; Criner, GJ; Gaggar, A; Gottlieb, RL; Huhn, G; Hyland, RH; Le Turnier, P; Malhotra, P; Marty, FM; McPhail, MJ; Mullane, KM; Ogbuagu, O; Osinusi, AO; Roestenberg, M; Sanyal, AJ; SenGupta, D; Soriano Viladomiu, A; Spinner, CD; Tsang, OTY; Wang, H, 2020
)
" Therapies dosed soon after peak viral load when symptoms develop may decrease shedding duration and immune response intensity but have little effect on viral area under the curve (AUC), which is driven by high early viral loads."( Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response.
Cardozo-Ojeda, EF; Goyal, A; Schiffer, JT, 2020
)
" This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD."( Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function.
Govil, A; Luckett, K; Miller-Handley, H, 2020
)
" Recommendations were made based on available data, consideration of pharmacokinetic properties (including variability), the dosing and anticipated treatment duration of each regimen in COVID-19 and known toxicities."( Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
Back, D; Boyle, A; Burger, D; Davidson, K; El-Sherif, O; Gibbons, S; Khoo, S; Marra, F; Marzolini, C; Siccardi, M; Smolders, EJ; Sommerville, AJ, 2021
)
" As opposed to intravenous injection, extended release subcutaneous injection has the benefits of reducing face-to-face contact, minimizing hospitalization, reducing dosing frequency and reducing overall health care cost."( Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment.
Palekar, S; Patel, K; Patki, M; Reznik, S, 2021
)
" However, should some hospitalized patients have dosage escalation to intermediate dose? Should some be considered for full-dose anticoagulation without a measurable thromboembolic event and how should that anticoagulation be monitored? Should patients receive postdischarge anticoagulation and with what medication and for how long? What thrombotic issues are related to the various medications being used to treat this coagulopathy? Is antiphospholipid antibody part of this syndrome? What is the significance of isolated ischemic stroke and limb ischemia in this disorder and how does this interface with the rest of the clinical and laboratory features of this disorder? The aims of this article are to explore these questions and interpret the available data based on the current evidence."( COVID-19 and Its Implications for Thrombosis and Anticoagulation.
Berkman, SA; Tapson, VF, 2021
)
" We describe utilizing the recall antigen assay platform to screen small molecule drug off-target effects on memory T cell expansion/function using a dosing regimen based on adenosine treatment."( Adenosine-related small molecules show utility of recall antigen assay to screen compounds for off-target effects on memory T cells.
Daftarian, PM; George, MV; Kleiman, E; Magcase, D; Mao, B; Sierra, G, 2021
)
" Frequent dosing is therefore required, which needs expert personnel and multiple hospital visits and can result in serious side effects."( Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment
Kunda, NK; Patel, K; Patil, SM; Patki, M; Saraswat, A; Vartak, R, 2021
)
" Low-dose radiation (LDR), at a much lower dosage than applied in cancer treatment, re-emerged after a 75-year silence in its use in unresolved pneumonia, as a scientific interest with surprising effects in soothing the cytokine storm and other symptoms in severe COVID-19 patients."( COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation.
Azzam, EI; Jadhav, AB; Wang, Y; Yu, J, 2021
)
" These predictions along with the organ impairment study results may be used to support decision making regarding the RDV dosage adjustment in these patient subgroups."( Whole Body PBPK Modeling of Remdesivir and Its Metabolites to Aid in Estimating Active Metabolite Exposure in the Lung and Liver in Patients With Organ Dysfunction.
Arya, V; Earp, JC; Fan, J; Grimstein, M; Kitabi, E; Reynolds, KS; Wang, Y; Yang, Y; Zhang, X; Zhu, H, 2022
)
" Its clinical efficacy has been evaluated, but needs to be optimized with regard to timing, dosage and duration of treatment, and route of administration."( Remdesivir: Quo vadis?
De Clercq, E, 2021
)
" We found that mean (standard deviation) recovery of RDV at 6 hours after dosing was low in both the ECMO (33."( Remdesivir and GS-441524 Extraction by Ex Vivo Extracorporeal Life Support Circuits.
Green, DJ; Imburgia, CE; Kelley, WE; Mcknite, AM; Reilly, CA; Rower, JE; Watt, KM, 2022
)
"This is an open-label, randomized, fixed sequence single intravenous dosing study to assess pharmacokinetic interactions between remdesivir and TDF/3TC (Study A, crossover design) or TDF/3TC plus ATV/r (Study B)."( An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR).
Byakika-Kibwika, P; D'Avolio, A; Kaboggoza, JP; Lamorde, M; Waitt, C; Walimbwa, SI, 2021
)
" Inhalation RDV dosing resulted in lower systemic exposures to RDV and its metabolites as compared with IV RDV dosing."( Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection.
Babusis, D; Bannister, R; Bilello, JP; Cihlar, T; Ellis, S; Gigliotti, A; Hartke, J; Irshad, H; Kadrichu, N; Kim, C; Kuehl, PJ; Lee, WA; Ma, B; Mackman, RL; Murakami, E; Niu, C; Pitts, J; Porter, DP; Rautiola, D; Seigel, D; Smith, B; Subramanian, R; Tomkinson, A; Vermillion, MS; Yang, J; Zhao, X, 2022
)
" Alternative dosing regimens were evaluated using Monte Carlo simulations."( Population Pharmacokinetics of Remdesivir and GS-441524 in Hospitalized COVID-19 Patients.
Bosma, LBE; Leegwater, E; Moes, DJAR; Ottens, TH; van der Meer, IM; van Nieuwkoop, C; Wilms, EB, 2022
)
" In conclusion, the representative F5 bio-SNEDDS could be a promising candidate for improving the anticancer effect of remdesivir and baricitinib along with their existing antiviral performance in combined dosage form."( Oral Bioactive Self-Nanoemulsifying Drug Delivery Systems of Remdesivir and Baricitinib: A Paradigmatic Case of Drug Repositioning for Cancer Management.
Alanazi, Y; Alghamdi, KM; Kazi, M; Kumar, A; Rizwan Ahamad, S; Shahba, AA, 2023
)
" On 3 dpi, one group received a loading dose of 10 mg/kg remdesivir followed by daily dosing with 5 mg/kg for 11 days, one group received 10 mg/kg on 12 consecutive days, and the remaining group received an equivalent volume of vehicle solution."( Late remdesivir treatment initiation partially protects African green monkeys from lethal Nipah virus infection.
Bunyan, E; Cihlar, T; de Wit, E; Feldmann, F; Feldmann, H; Goldin, K; Lo, MK; Lovaglio, J; Okumura, A; Porter, DP; Saturday, G; Spiropoulou, CF; Williamson, BN, 2023
)
"Cats received treatment with different combinations of IV remdesivir, SC remdesivir, and PO GS-441524 at a median (range) dosage of 15 (10-20) mg/kg."( Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524.
Green, J; Syme, H; Tayler, S,
)
" An induction dosage of remdesivir 10 to 15 mg/kg intravenously or subcutaneously q24h was utilized for 4 doses, with a maintenance dosage of remdesivir (6-15 mg/kg SC) or GS-441524 (10-15 mg/kg per os) every 24 hours continued for at least 84 days."( Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524.
Coggins, SJ; Govendir, M; Hall, EJ; Kimble, B; Malik, R; Norris, JM; Thompson, MF,
)
" Remission was achieved in all 3 after higher dosing (15-20 mg/kg)."( Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524.
Coggins, SJ; Govendir, M; Hall, EJ; Kimble, B; Malik, R; Norris, JM; Thompson, MF,
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antiviral drugA substance used in the prophylaxis or therapy of virus diseases.
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
carboxylic esterAn ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl.
pyrrolotriazineAny organic heterobicyclic compound containing ortho-fused pyrrolidine and triazine rings.
nitrileA compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it.
phosphoramidate esterA phosphoric ester (phosphate) that has an NR2 instead of an OH group.
C-nucleoside
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Nsp9 interactions (COVID-19 Disease Map)8330

Protein Targets (11)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NS5 Zika virusIC50 (µMol)1.36001.18001.38671.6200AID1895558
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)5.10200.00022.45859.9600AID1772418; AID1772421; AID1772422; AID1804171
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinBetacoronavirus England 1EC50 (µMol)0.77000.00304.57559.8200AID1804127
Replicase polyprotein 1abBetacoronavirus England 1EC50 (µMol)0.77000.00304.57559.8200AID1804127
Transmembrane protease serine 2Homo sapiens (human)EC50 (µMol)0.77000.00304.51689.8200AID1804127
Procathepsin LHomo sapiens (human)EC50 (µMol)0.77000.00304.48749.8200AID1804127
Replicase polyprotein 1aSevere acute respiratory syndrome-related coronavirusEC50 (µMol)0.77000.00304.61369.8200AID1804127
Replicase polyprotein 1abHuman coronavirus 229EEC50 (µMol)0.77000.00304.61369.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusEC50 (µMol)0.77000.00304.45549.8200AID1804127
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2EC50 (µMol)0.71000.00304.11059.8200AID1804127; AID1805295; AID1805296
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusEC50 (µMol)0.77000.00304.57559.8200AID1804127
Angiotensin-converting enzyme 2 Homo sapiens (human)EC50 (µMol)0.77000.00304.57559.8200AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (48)

Processvia Protein(s)Taxonomy
viral translationTransmembrane protease serine 2Homo sapiens (human)
proteolysisTransmembrane protease serine 2Homo sapiens (human)
protein autoprocessingTransmembrane protease serine 2Homo sapiens (human)
positive regulation of viral entry into host cellTransmembrane protease serine 2Homo sapiens (human)
adaptive immune responseProcathepsin LHomo sapiens (human)
proteolysisProcathepsin LHomo sapiens (human)
protein autoprocessingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host plasma membraneProcathepsin LHomo sapiens (human)
receptor-mediated endocytosis of virus by host cellProcathepsin LHomo sapiens (human)
antigen processing and presentationProcathepsin LHomo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class IIProcathepsin LHomo sapiens (human)
collagen catabolic processProcathepsin LHomo sapiens (human)
zymogen activationProcathepsin LHomo sapiens (human)
enkephalin processingProcathepsin LHomo sapiens (human)
fusion of virus membrane with host endosome membraneProcathepsin LHomo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitmentProcathepsin LHomo sapiens (human)
symbiont entry into host cellProcathepsin LHomo sapiens (human)
antigen processing and presentation of peptide antigenProcathepsin LHomo sapiens (human)
proteolysis involved in protein catabolic processProcathepsin LHomo sapiens (human)
elastin catabolic processProcathepsin LHomo sapiens (human)
macrophage apoptotic processProcathepsin LHomo sapiens (human)
cellular response to thyroid hormone stimulusProcathepsin LHomo sapiens (human)
positive regulation of apoptotic signaling pathwayProcathepsin LHomo sapiens (human)
positive regulation of peptidase activityProcathepsin LHomo sapiens (human)
immune responseProcathepsin LHomo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
negative regulation of signaling receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cytokine productionAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin maturationAngiotensin-converting enzyme 2 Homo sapiens (human)
angiotensin-mediated drinking behaviorAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensinAngiotensin-converting enzyme 2 Homo sapiens (human)
tryptophan transportAngiotensin-converting enzyme 2 Homo sapiens (human)
viral life cycleAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated endocytosis of virus by host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of vasoconstrictionAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of transmembrane transporter activityAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cell population proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
symbiont entry into host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of smooth muscle cell proliferationAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of inflammatory responseAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of amino acid transportAngiotensin-converting enzyme 2 Homo sapiens (human)
maternal process involved in female pregnancyAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of cardiac muscle contractionAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane fusionAngiotensin-converting enzyme 2 Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeAngiotensin-converting enzyme 2 Homo sapiens (human)
blood vessel diameter maintenanceAngiotensin-converting enzyme 2 Homo sapiens (human)
entry receptor-mediated virion attachment to host cellAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of gap junction assemblyAngiotensin-converting enzyme 2 Homo sapiens (human)
regulation of cardiac conductionAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of L-proline import across plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityTransmembrane protease serine 2Homo sapiens (human)
protein bindingTransmembrane protease serine 2Homo sapiens (human)
serine-type peptidase activityTransmembrane protease serine 2Homo sapiens (human)
fibronectin bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activityProcathepsin LHomo sapiens (human)
protein bindingProcathepsin LHomo sapiens (human)
collagen bindingProcathepsin LHomo sapiens (human)
cysteine-type peptidase activityProcathepsin LHomo sapiens (human)
histone bindingProcathepsin LHomo sapiens (human)
proteoglycan bindingProcathepsin LHomo sapiens (human)
serpin family protein bindingProcathepsin LHomo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic processProcathepsin LHomo sapiens (human)
RNA-dependent RNA polymerase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
virus receptor activityAngiotensin-converting enzyme 2 Homo sapiens (human)
endopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
carboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
metallocarboxypeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
metallopeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
peptidyl-dipeptidase activityAngiotensin-converting enzyme 2 Homo sapiens (human)
zinc ion bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
identical protein bindingAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
extracellular regionTransmembrane protease serine 2Homo sapiens (human)
nucleoplasmTransmembrane protease serine 2Homo sapiens (human)
plasma membraneTransmembrane protease serine 2Homo sapiens (human)
extracellular exosomeTransmembrane protease serine 2Homo sapiens (human)
extracellular regionProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
nucleusProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
multivesicular bodyProcathepsin LHomo sapiens (human)
Golgi apparatusProcathepsin LHomo sapiens (human)
plasma membraneProcathepsin LHomo sapiens (human)
apical plasma membraneProcathepsin LHomo sapiens (human)
endolysosome lumenProcathepsin LHomo sapiens (human)
chromaffin granuleProcathepsin LHomo sapiens (human)
lysosomal lumenProcathepsin LHomo sapiens (human)
intracellular membrane-bounded organelleProcathepsin LHomo sapiens (human)
collagen-containing extracellular matrixProcathepsin LHomo sapiens (human)
extracellular exosomeProcathepsin LHomo sapiens (human)
endocytic vesicle lumenProcathepsin LHomo sapiens (human)
extracellular spaceProcathepsin LHomo sapiens (human)
lysosomeProcathepsin LHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1aSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular regionAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
endoplasmic reticulum lumenAngiotensin-converting enzyme 2 Homo sapiens (human)
plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
ciliumAngiotensin-converting enzyme 2 Homo sapiens (human)
cell surfaceAngiotensin-converting enzyme 2 Homo sapiens (human)
membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
apical plasma membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
endocytic vesicle membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
brush border membraneAngiotensin-converting enzyme 2 Homo sapiens (human)
membrane raftAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular exosomeAngiotensin-converting enzyme 2 Homo sapiens (human)
extracellular spaceAngiotensin-converting enzyme 2 Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (253)

Assay IDTitleYearJournalArticle
AID1764954Drug metabolism in cynomolgus monkey assessed as total metabolite concentration in kidney at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1440681Antiviral activity against Ebolavirus infected in rhesus monkey assessed as survival rate at 3 mg/kg, iv qd administered continuously starting from day 3 post infection for 12 days measured on day 28 (Rvb = 33%)2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1684808Antiviral activity against SARS-CoV-2 UC-1075 infected in African green monkey Vero cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection by microscopic analysis2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID1440658Cytotoxicity against human MT4 cells assessed as reduction in cell viability after 4 to 5 days by Cell-Titer Glo assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1785774Antiviral activity against SARS-CoV-2 C-Tan-nCoV Wuhan strain 01 virus infected in Hamster rat assessed as widening of perivascular interstitium at 5 mg/kg, inh administered for 3 days starting from 1 hr post infection and measured on day 4 by histopathol
AID1440654Antiviral activity against Respiratory syncytial virus A2 infected in human Hep2 cells assessed as reduction of virus-induced cytopathic effect after 4 days by Cell-Titer Glo assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1766131Cytotoxicity against African green monkey Vero E6 cells after 72 hrs by MTT assay2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.
AID1440685Drug uptake in cynomolgus monkey epididymis at 10 mg/kg, iv at 4 hrs post dose2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1440690Toxicity in iv dosed phase-1 acute meningoencephalytis patient administered as single dose2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1682557Cytotoxicity against African green monkey Vero cells infected with SARS-CoV-2 betaCoV/KOR/KCDC03/2020 assessed as reduction in cell viability measured after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2.
AID1440655Antiviral activity against Hepatitis C virus genotype 1b infected in human HuH7 cells preincubated with cells for 3 days followed by viral infection by luciferase assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1764927Terminal half life in African green monkey at 10 mg/kg, iv after 30 mins by LC-MS/MS analysis
AID1811335Selectivity index, ratio of CC50 for African green monkey Vero cells to EC50 for SARS-CoV-2 nCoV-2019 BetaCoV/Wuhan/WIV04/2019 infected in African green monkey VeroE6 cells2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1785772Antiviral activity against SARS-CoV-2 C-Tan-nCoV Wuhan strain 01 virus infected in Hamster rat assessed as widening of alveolar septum at 5 mg/kg, inh administered for 3 days starting from 1 hr post infection and measured on day 4 by histopathological ana
AID1764959Antiviral activity against RSV A2 infected in african green monkey assessed as reduction in BAL viral load at 10 mg/kg, iv administered 4 hrs prior to viral infection and daily upto 5 days post infection and measured every other day until day 15 by RT-qPC
AID1440683Antiviral activity against Ebolavirus infected in rhesus monkey assessed as viral RNA copies at 10 mg/kg, iv administered daily administered daily starting from day 3 post infection measured on day 5 and 7 (Rvb = 10'9 copies/ml)2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1815329Antiviral activity against Severe acute respiratory syndrome coronavirus 2 UC-1075 infected in African green monkey Vero cells assessed as reduction in plaque formation measured after 5 days by microscopic analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.
AID1856553Antiviral activity against SARS-CoV-2 infected in human A549-ACE2 cells assessed as effect on cell viability pretreated with compound for 1 hr followed by viral infection measured after 2 hrs by Nano-Glo reagent based LDH assay2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Identification and Utilization of a Chemical Probe to Interrogate the Roles of PIKfyve in the Lifecycle of β-Coronaviruses.
AID1783394Selectivity index, ratio of CC50 for African green monkey Vero E6 cells infected with SARS-COV-2 to IC50 for SARS-COV 2 infected in monkey Vero E6 cells2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1918727Cytotoxicity against human HCT-8 cells assessed as redcution in cell viability incubated for 96 hrs by PrestoBlue reagent based assay2022Journal of natural products, 12-23, Volume: 85, Issue:12
Evaluating the
AID1440693Toxicity in phase-1 acute meningoencephalytis patient at 150 mg, iv qd administered daily for 2 days followed by 225 mg for 14 days2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1717757Cytotoxicity against human Huh-7 cells by CellTiter-Glo assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1467733Antiviral activity against Ebolavirus infected in human HuH7 cells after 3 days by end point dilution assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1898550Antiviral activity against Human coronavirus 229E infected in human MRC5 cells assessed as reduction in virus-induced cytopathic effect incubated for 3 days by Celltiter-Glo assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
AID1811331Antiviral activity against Ebola virus trVLP assessed as reduction in RNA synthesis at 1 uM by qPCR analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1717748Antiviral activity against 2019-nCoV BetaCoV/Wuhan/WIV04/2019 infected in African green monkey VeroE6 cells assessed as reduction in viral yield preincubated with virus for 1 hr followed by cell infection and measured after 2 hrs by qRT-PCR method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1785769Antiviral activity against SARS-CoV-2 C-Tan-nCoV Wuhan strain 01 virus infected in Hamster rat assessed as widening of perivascular interstitium at 25 mg/kg, inh administered for 3 days starting from 1 hr post infection and measured on day 4 by histopatho
AID1811322Antiviral activity against Ebola virus constitutively expressed firefly infected in human Huh-7 cells expressing pretreated for 1 hrs followed by viral infection and measured after 24 hrs by dual luciferase reporter assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1764951Drug metabolism in cynomolgus monkey assessed as total metabolite concentration in liver at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1898395Half life in human plasma at 3 to 225 mg, iv administered as 2 hr infusion2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.
AID1881735Antiviral activity against SARS CoV-2 infected in African green monkey Vero E6 cells incubated for 2 hrs by CellTiter-Glo luminescent cell viability assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1811314Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Antiviral activity against Ebola virus trVLP infected in human Huh-7 cells2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1881739Stability in wild type C57BL/6J mouse model infected with MERS-CoV assessed as half life at 25 mg/kg, sc bid pre-infected with virus for 1 day followed by compound treatment measured up to 6 days2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1467737Half life in rhesus monkey plasma at 10 mg/kg, iv administered as bolus dose by LC-MS/MS analysis2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1717760Cytotoxicity against human Huh7 cells incubated for 6 days by cellTiter-Glo assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1881678Antiviral activity against SARS CoV-2 infected in HAE cells measured after 48 hrs by plaque assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1881738Stability in Ces1c knockout C57BL/6J mouse model infected with MERS-CoV assessed as half life at 25 mg/kg, sc bid pre-infected with virus for 1 day followed by compound treatment measured up to 6 days2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1898394AUC in human plasma at 3 to 225 mg, iv administered as 2 hr infusion2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.
AID1895558Inhibition of Zika virus RNA-dependent RNA polymerase activity2021European journal of medicinal chemistry, Nov-15, Volume: 224Insights on Dengue and Zika NS5 RNA-dependent RNA polymerase (RdRp) inhibitors.
AID1440660Selectivity ratio of CC50 for human MT4 cells to EC50 for Ebolavirus infected in TERT-immortalized HMVEC2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1783393Antiviral activity against SARS-COV 2 infected in monkey Vero E6 cells assessed as inhibition of viral replication at MOI of 0.01 and incubated after 2 hrs post infection for 48 hrs by direct yield reduction assay2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1440659Selectivity ratio of CC50 for human MT4 cells to EC50 for Ebolavirus infected in human HeLa cells2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1764938Drug metabolism in african green monkey assessed as 1-NTP metabolite concentration in lung tissue at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1440656Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 4 to 5 days by Cell-Titer Glo assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1764918Drug metabolism in human HEp-2 cells assessed as 1-NTP metabolite concentration at 1 uM over 48 hrs by LC-MS/MS analysis
AID1764953Drug metabolism in african green monkey assessed as total metabolite concentration in kidney at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1785773Antiviral activity against SARS-CoV-2 C-Tan-nCoV Wuhan strain 01 virus infected in Hamster rat assessed as widening of bronchus at 5 mg/kg, inh administered for 3 days starting from 1 hr post infection and measured on day 4 by histopathological analysis
AID1785765Antiviral activity against SARS-CoV-2 C-Tan-nCoV Wuhan strain 01 infected in African green monkey Vero cells assessed as inhibition of viral replication measured after 48 hrs by RT-qPCR method
AID1783397Selectivity index, ratio of CC50 for human Calu-3 cells infected with SARS-COV-2 to IC50 for SARS-COV 2 infected in human Calu-3 cells2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1661020Half life in serum of rhesus monkey Infected with SARS-CoV-2 at 10 mg/kg, iv dosed 12 hrs after postinoculation with SARSCoV-2 and then followed by 5 mg/kg, iv dosed every 24 hrs2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.
AID1764929AUCinfinity in African green monkey at 10 mg/kg, iv after 30 mins by LC-MS/MS analysis
AID1772419Cytotoxicity against human HEK293T cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.
AID1764957Cmax in cynomolgus monkey at 10 mg/kg, iv after 30 mins by LC-MS/MS analysis
AID1764921Drug metabolism in human HEp-2 cells assessed as 1-NTP metabolite concentration at EC50 over 48 hrs by LC-MS/MS analysis
AID1684806Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID1785767Antiviral activity against SARS-CoV-2 C-Tan-nCoV Wuhan strain 01 virus infected in Hamster rat assessed as widening of alveolar septum at 25 mg/kg, inh administered for 3 days starting from 1 hr post infection and measured on day 4 by histopathological an
AID1440692Antiviral activity against Ebolavirus in phase-1 acute meningoencephalytis patient assessed as viral clearance in CNS at 150 mg, iv qd administered daily for 2 days followed by 225 mg for 14 days2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1774053Antiviral activity against SARS-CoV-2 JPN/TY/WK-251 infected in Vero E6 cells assessed as reduction in number of infected cells at 100 uM after 3 days by immunocytochemistry analysis2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.
AID1764961Antiviral activity against RSV A2 infected in african green monkey assessed as reduction in viral replication in lung lavage samples at 10 mg/kg, iv administered 4 hrs prior to viral infection and daily upto 5 days post infection and measured every other
AID1440684Drug uptake in cynomolgus monkey testes at 10 mg/kg, iv at 4 hrs post dose2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1678482Antiviral activity against SARS-CoV-2 infected in Vero E6 cells preincubated for 1 hr followed by viral infection at MOI of 0.02 and measured after 48 hrs by qRT-PCR method2020ACS medicinal chemistry letters, Dec-10, Volume: 11, Issue:12
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2.
AID1467734Cytotoxicity against human primary macrophages after 4 to 5 days by Cell-Titer Glo viability assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1764948Drug metabolism in cynomolgus monkey assessed as 1-NTP metabolite concentration in trachea at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1881734Antiviral activity against SARS CoV-2 infected in human Calu-3 cells measured after 48 hrs by plaque assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1811321Antiviral activity against Ebola virus trVLP infected in human Huh-7 cells pretreated for 1 hrs followed by viral infection and measured after 24 hrs by dual luciferase reporter assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1893718Antiviral activity against SARS-CoV-2 infected in human A549 cells overexpressing ACE2 and TMPRSS2 assessed as reduction in viral growth incubated for 48 hrs by DAPI staining based immunofluorescence assay
AID1880951Cytotoxicity against human Calu-3 cells assessed as reduction in cell virion production at 10 uM incubated for 24 hrs by cell titer glo luminescent assay
AID1877267Antiviral activity against Severe acute respiratory syndrome coronavirus 2 infected in African green monkey Vero E6 cells assessed as inhibition of viral cytopathic effect at 0.064 uM incubated for 72 hrs by CCK8 assay relative to control2022European journal of medicinal chemistry, Jan-05, Volume: 227Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2.
AID1877268Antiviral activity against Severe acute respiratory syndrome coronavirus 2 infected in African green monkey Vero E6 cells assessed as inhibition of viral cytopathic effect at 0.32 uM incubated for 72 hrs by CCK8 assay relative to control2022European journal of medicinal chemistry, Jan-05, Volume: 227Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2.
AID1811316Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to IC50 for Antiviral activity against SARS coronavirus 2 USA/WA1/2020 infected in Vero E6 cells assessed as reduction in virus-induced cytopathic effect2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1785776Antiviral activity against SARS-CoV-2 C-Tan-nCoV Wuhan strain 01 virus infected in Hamster rat assessed as infiltration of neutrophils at 5 mg/kg, inh administered for 3 days starting from 1 hr post infection and measured on day 4 by histopathological ana
AID1783388Selectivity index, ratio of CC50 for human Huh-7 cells infected with SARS-COV-2 to IC50 for SARS-COV 2 infected in human Huh-72021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1440687Drug metabolism in cynomolgus monkey testes at 10 mg/kg, iv after 168 hrs post dose2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1815251Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero E6 cells to EC50 for antiviral activity against SARS-COV2/NL/2020 infected in African green monkey Vero E6 cells2021European journal of medicinal chemistry, Dec-15, Volume: 226Indomethacin-based PROTACs as pan-coronavirus antiviral agents.
AID1811317Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability after 48 hrs by Cell-Tox green based fluorescence assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1881737Antiviral activity against SARS CoV-2 infected in human Huh-7 cells measured up to 72 hrs by plaque assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1766127Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as inhibition of viral replication measured after 48 hrs by qRT-PCR method2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.
AID1881731Antiviral activity against SARS CoV infected in HAE cells measured after 48 hrs by CellTiter-Glo assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1764902Antiviral activity against RSV A2 infected in HEp-2 cells assessed as reduction in virus-induced cytopathic effect after 4 days by CellTiter Glo viability assay
AID1764950Drug metabolism in african green monkey assessed as total metabolite concentration in liver at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1764925Clearance in African green monkey at 10 mg/kg, iv after 30 mins by LC-MS/MS analysis
AID1764922Drug metabolism in NHBE cells assessed as 1-NTP metabolite concentration at EC50 over 48 hrs by LC-MS/MS analysis
AID1717763Cytotoxicity against HAE cells by CellTiter-Glo assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1877261Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay2022European journal of medicinal chemistry, Jan-05, Volume: 227Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2.
AID1440694Antiviral activity against Ebolavirus infected in newborn infant assessed as viral clearance2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1772420Inhibition of SARS-CoV-2 RdRp transfected in HEK293T cells cotransfected with CoV-Gluc assessed as decrease in plus and minus strand-Gluc RNA levels incubated for 24 hrs by qRT-PCR analysis2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.
AID1918731Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells to IC50 for antiviral activity against SARS-CoV-2 infected in African green monkey Vero cells2022Journal of natural products, 12-23, Volume: 85, Issue:12
Evaluating the
AID1811326Drug metabolism in human plasma assessed as active triphosphate metabolite formation at 10 uM after 12 hrs by LC-QTOF-MS analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1682556Antiviral activity against SARS-CoV-2 betaCoV/KOR/KCDC03/2020 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect measured after 24 hrs by immunofluorescence assay2021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2.
AID1440679Half life in rhesus monkey PBMC assessed as ((2R,3S,4R,5R)-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate levels at 10 mg/kg, iv administered as single bolus2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1881736Antiviral activity against SARS CoV-2 infected in African green monkey Vero E6 cells assessed as inhibition of virus-induced cytopathic effect measured after 72 hrs by Reed-Muench method2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1684809Antiviral activity against SARS-CoV-2 UC-1074 infected in African green monkey Vero cells assessed as reduction in virus plaque formation measured on day 5 post-viral infection by microscopic analysis2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID1467732Antiviral activity against Ebolavirus infected in human HeLa cells after 48 hrs by immuno-staining assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1811318Antiviral activity against SARS coronavirus 2 USA/WA1/2020 infected in Calu-3 cells assessed as reduction in virus-induced cytopathic effect preincubated for 1 hr followed by viral infection and measured after 48 hrs2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1811320Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 24 hrs by CellTiter-Glo analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1764935Drug metabolism in african green monkey assessed as 1-NTP metabolite concentration in PBMC at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1440674Half life in human plasma at 2 uM by LC/MS/MS analysis2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1877271Antiviral activity against Severe acute respiratory syndrome coronavirus 2 infected in African green monkey Vero E6 cells assessed as inhibition of viral cytopathic effect at 40 uM incubated for 72 hrs by CCK8 assay relative to control2022European journal of medicinal chemistry, Jan-05, Volume: 227Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2.
AID1898371Antiviral activity against SARS-COV 2 infected in human Calu-3 cells assessed as inhibition of viral replication after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.
AID1764919Drug metabolism in normal human bronchial epithelial cells assessed as 1-NTP metabolite concentration at 1 uM over 48 hrs by LC-MS/MS analysis
AID1772424Antiviral activity against HCoV-OC43 infected in HCT-8 cells assessed as reduction in viral replication treated 1 hr post infection and measured after 120 hrs post infection by MTS cell proliferation colorimetric assay2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.
AID1811323Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Antiviral activity against Ebola virus constitutively expressed firefly2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1467739Antiviral activity against Ebolavirus H. sapiens-tc/COD/1995/Kikwit infected in rhesus monkey assessed as host survival at 3 mg/kg, iv administered as bolus dose2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1764913Selectivity index, ratio of CC50 for human HEp-2 cells to EC50 for RSV A2 infected in HEp-2 cells
AID1865408Antiviral activity against SARS-CoV-2 infected in human 293TA cells assessed as reduction in cytopathic effect after 2 to 3 days by MTT assay2022Journal of natural products, 11-25, Volume: 85, Issue:11
Dihydromaniwamycin E, a Heat-Shock Metabolite from Thermotolerant
AID1785771Antiviral activity against SARS-CoV-2 C-Tan-nCoV Wuhan strain 01 virus infected in Hamster rat assessed as infiltration of neutrophils at 25 mg/kg, inh administered for 3 days starting from 1 hr post infection and measured on day 4 by histopathological an
AID1766168Antiviral activity against SARS-CoV-2 nCoV-2019BetaCoV/Wuhan/WIV04/ infected in African green monkey Vero E6 cells assessed as inhibition of viral replication when host cells were pretreated for 1 hr followed by viral infection then followed by removal of2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2.
AID1811337Antiviral activity against SARS Cov-2 USA_WA1/2020 infected in HAE cells measured upto 72 hrs by qRT-PCR method2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1880956Cytotoxicity against African green monkey Vero 76 cells assessed as reduction in cell virion production at 10 uM incubated for 24 hrs by cell titer glo luminescent assay
AID1440676Drug metabolism in rhesus monkey PBMC assessed as ((2R,3S,4R,5R)-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate levels at 10 mg/kg, iv administered as single bolus dose up to 2 hrs2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1783390Cytotoxicity against human Caco2 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1774049Antiviral activity against SARS-CoV-2 JPN/TY/WK-251 infected in Vero E6 cells after 72 hrs by RT-qPCR analysis2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.
AID1467731Antiviral activity against Ebolavirus infected in human primary macrophages after 48 hrs by immuno-staining assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1764942Drug metabolism in cynomolgus monkey assessed as 1-NTP metabolite concentration in lower bronchi at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1783391Antiviral activity against SARS-COV 2 infected in human Caco-2 cells assessed as inhibition of viral replication at MOI of 0.01 and incubated after 2 hrs post infection for 48 hrs by immunodetection assay2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1918732Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay2022Journal of natural products, 12-23, Volume: 85, Issue:12
Evaluating the
AID1772423Ratio of IC50 for inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12 along with nsp14/nsp10 to IC50 for inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with nsp122021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.
AID1661022Antiviral activity against SARS coronavirus infected in primary HAE cells2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.
AID1785770Antiviral activity against SARS-CoV-2 C-Tan-nCoV Wuhan strain 01 virus infected in Hamster rat assessed as infiltration of lymphocytes at 25 mg/kg, inh administered for 3 days starting from 1 hr post infection and measured on day 4 by histopathological an
AID1733128Antiviral activity against SARS coronavirus 2 infected in Vero E6 cells assessed as plague reduction measured after 1 hr2021European journal of medicinal chemistry, Apr-05, Volume: 215A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
AID1764916Antiviral activity against RSV A2 infected in HAE cells assessed as reduction in viral load at 0.25 uM after 3 days by RT-qPCR analysis
AID1440651Lipophilicity, log D of the compound after 30 mins by HPLC/UV method2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1815253Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero E6 cells to EC50 for antiviral activity against SARS-COV2/Padova/2020 infected in African green monkey Vero E6 cells2021European journal of medicinal chemistry, Dec-15, Volume: 226Indomethacin-based PROTACs as pan-coronavirus antiviral agents.
AID1717759Antiviral activity against HCoV-229E infected in human Huh7 cells assessed as reduction in virus induced cytopathic effect incubated for 6 days by cellTiter-Glo assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1774051Antiviral activity against SARS-CoV-2 JPN/TY/WK-251 infected in Vero E6 cells assessed as reduction in cytopathic effect at 1 to 100 uM after 72 hrs by RT-qPCR analysis2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.
AID1865409Antiviral activity against SARS-CoV-2 infected in African green monkey VeroE6T cells assessed as reduction in cytopathic effect after 2 to 3 days by MTT assay2022Journal of natural products, 11-25, Volume: 85, Issue:11
Dihydromaniwamycin E, a Heat-Shock Metabolite from Thermotolerant
AID1764945Drug metabolism in cynomolgus monkey assessed as 1-NTP metabolite concentration in main stem bronchi at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1916052Antiviral activity against SARS 2019-nCoV infected in African green monkey Vero E6 cells assessed as inhibition of viral infection preincubated and measured after 48 hrs by qRT-PCR analysis2021European journal of medicinal chemistry, Aug-05, Volume: 220Tailor-made amino acids in the design of small-molecule blockbuster drugs.
AID1467738Half life in rhesus monkey PBMC at 10 mg/kg, iv administered as bolus dose by LC-MS/MS analysis2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1440682Antiviral activity against Ebolavirus infected in rhesus monkey assessed as increase in survival at 10 mg/kg, iv administered daily starting from day 3 post infection followed by 3 mg/kg for 11 days measured up to 28 days2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1881733Antiviral activity against SARS CoV-2 infected in African green monkey Vero E6 cells measured after 48 hrs by plaque assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1783396Antiviral activity against SARS-COV 2 infected in human Calu-3 cells assessed as inhibition of viral replication at MOI of 0.01 and incubated after 2 hrs post infection for 48 hrs by direct yield reduction assay2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1717761Selectivity ratio of CC50 for human Huh7 cells to EC50 for HCoV-229E infected in human Huh-7 cells2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1764947Drug metabolism in african green monkey assessed as 1-NTP metabolite concentration in trachea at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1764936Drug metabolism in cynomolgus monkey assessed as 1-NTP metabolite concentration in PBMC at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1851895Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as inhibition of viral replication incubated for 25 to 26 hrs by EliSpot reader based analysis2022Journal of medicinal chemistry, 10-13, Volume: 65, Issue:19
Discovery and Crystallographic Studies of Trisubstituted Piperazine Derivatives as Non-Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity and Low Toxicity.
AID1783387Antiviral activity against SARS-COV 2 infected in human Huh-7 cells assessed as inhibition of viral replication at MOI of 0.01 and incubated after 2 hrs post infection for 48 hrs by direct yield reduction assay2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1783363Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1783389Cytotoxicity against African green monkey Vero E6 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1811319Selectivity index, ratio of CC50 for human Calu-3 cells to IC50 for Antiviral activity against SARS coronavirus 2 USA/WA1/2020 infected in human Calu3 cells assessed as reduction in virus-induced cytopathic effect2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1764926Volume of distribution at steady state in African green monkey at 10 mg/kg, iv after 30 mins by LC-MS/MS analysis
AID1764939Drug metabolism in cynomolgus monkey assessed as 1-NTP metabolite concentration in lung tissue at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1766126Antiviral activity against SARS-CoV-2 infected in 16HBE14o- cells assessed as inhibition of viral replication after 1 day by Nano-Glo luciferase assay2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.
AID1783341Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1783395Cytotoxicity against human Calu-3 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1895557Inhibition of DENV RNA-dependent RNA polymerase activity2021European journal of medicinal chemistry, Nov-15, Volume: 224Insights on Dengue and Zika NS5 RNA-dependent RNA polymerase (RdRp) inhibitors.
AID1811324Antiviral activity against wild type Ebola virus infected in human HeLa cells assessed as reduction in viral infection measured after 24 hrs by Hoechst 33342 staining based microscopic analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1898372Antiviral activity against SARS-COV 2 infected in African green monkey Vero E6 cells assessed as inhibition of viral replication after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.
AID1918730Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay2022Journal of natural products, 12-23, Volume: 85, Issue:12
Evaluating the
AID1440657Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 3 days by calcein-AM dye based fluorescence assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1783340Antiviral activity against Influenza A Puerto Rico/8/34/H1N1 infected in human A549 cells assessed as inhibition of viral replication after 24 hrs by hemagglutination assay2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1661025Antiviral activity against Middle East respiratory syndrome coronavirus infected in primary HAE cells2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.
AID1766132Cytotoxicity against human 16HBE14o- after 72 hrs by MTT assay2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.
AID1783422Antiviral activity against SARS-COV 2 infected in African green monkey Vero E6 cells2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1783386Cytotoxicity against human Huh-7 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1815252Antiviral activity against SARS-COV2/Padova/2020 infected in African green monkey Vero E6 cells assessed as inhibition of plaque formation measured after 3 days by Plaque reduction assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Indomethacin-based PROTACs as pan-coronavirus antiviral agents.
AID1467736Cytotoxicity against human HuH7 after 4 to 5 days by Cell-Titer Glo viability assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1783364Antiviral activity against Influenza A Puerto Rico/8/34/H1N1 infected in MDCK cells assessed as inhibition of viral replication measured in supernatants of infected cells after 24 hrs by hemagglutination assay2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1440673Antiviral activity against Ebolavirus Kikwit infected in human macrophages preincubated with cells for 2 hrs followed by viral infection measured after 48 hrs2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1811336Antiviral activity against SARS Cov-2 USA_WA1/2020 infected in human Calu-3 cells measured upto 72 hrs by qRT-PCR method2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1772421Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp122021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.
AID1764898Clearance in cynomolgus monkey at 10 mg/kg, iv after 30 mins by LC-MS/MS analysis
AID1918728Selectivity index, ratio of CC50 for cytotoxicity against human HCT-8 cells to IC50 for antiviral activity against HCoV-OC43 infected in human HCT-8 cells2022Journal of natural products, 12-23, Volume: 85, Issue:12
Evaluating the
AID1766166Antiviral activity against SARS-CoV-2 nCoV-2019BetaCoV/Wuhan/WIV04/ infected in African green monkey Vero E6 cells assessed as inhibition of viral replication at 5 uM when host cells were pretreated for 1 hr followed by viral infection then followed by re2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2.
AID1661021Half life carboxylesterase 1c deficient mouse2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.
AID1881732Antiviral activity against MARS CoV infected in HAE cells measured after 48 hrs by CellTiter-Glo assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
AID1918724Antiviral activity against HCoV-OC43 infected in human HCT-8 cells assessed as inhibition of viral growth at 10 uM incubated for 4 days by ELISA analysis relative to control2022Journal of natural products, 12-23, Volume: 85, Issue:12
Evaluating the
AID1877270Antiviral activity against Severe acute respiratory syndrome coronavirus 2 infected in African green monkey Vero E6 cells assessed as inhibition of viral cytopathic effect at 8 uM incubated for 72 hrs by CCK8 assay relative to control2022European journal of medicinal chemistry, Jan-05, Volume: 227Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2.
AID1890672Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability2022Journal of natural products, 03-25, Volume: 85, Issue:3
Marine Natural Products as Leads against SARS-CoV-2 Infection.
AID1815328Antiviral activity against Severe acute respiratory syndrome coronavirus 2 UC-1074 infected in African green monkey Vero cells assessed as reduction in plaque formation measured after 5 days by microscopic analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.
AID1440675Prodrug conversion in rhesus monkey plasma assessed as (2R,3R,4S,5R)-2-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile formation at 10 mg/kg, iv administered as single bolus dose2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1467730Half life in human primary macrophages assessed as nucleoside triphosphate level at 10 uM2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1764912Oral bioavailability in cynomolgus monkey at 20 mg/kg by LC-MS/MS method
AID1888678Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as virus-induced cytopathic effect at 5 uM measured after 48 hrs by CCK-8 assay2022Bioorganic & medicinal chemistry, 01-01, Volume: 53Synthesis and evaluation of enantiomers of hydroxychloroquine against SARS-CoV-2 in vitro.
AID1811327Drug metabolism in human plasma assessed as active triphosphate metabolite formation at 10 uM after 24 hrs by LC-QTOF-MS analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1440691Antiviral activity against Ebolavirus in phase-1 acute meningoencephalytis patient assessed as viral clearance in plasma at 150 mg, iv qd administered daily for 2 days followed by 225 mg for 14 days2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1877263Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero E6 cells to EC50 for antiviral activity against Severe acute respiratory syndrome coronavirus 2 infected in African green monkey Vero E6 cells2022European journal of medicinal chemistry, Jan-05, Volume: 227Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2.
AID1717749Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1897958Antiviral activity against SARS-CoV-2 infected in Vero E6 cells preincubated for 1 hr followed by methylcellulose addition and measured after 25 to 26 hrs by EliSpot reader based analysis2022Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
AID1717764Selectivity ratio of CC50 for HAE cells to EC50 for SARS-CoV expressing green fluorescent protein infected in human airway epithelial cells2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1785766Toxicity in Hamster rat infected with SARS-CoV-2 C-Tan-nCoV Wuhan strain 01 assessed as body weight loss at 25 mg/kg, inh measured after 4 days
AID1764903Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability incubated for 4 to 5 days by CellTiter Glo viability assay
AID1783420Antiviral activity against SARS-COV 2 infected in human Huh-7 cells2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1764907Lipophilicity, log D of compound in acetonitrile and water shaken for 30 mins by HPLC/UV analysis
AID1811315Antiviral activity against SARS Cov-2 USA/WA1/2020 infected in Vero E6 cells assessed as reduction in virus-induced cytopathic effect preincubated for 1 hr followed by viral infection and measured after 48 hrs post infection2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1467735Cytotoxicity against human HeLa after 4 to 5 days by Cell-Titer Glo viability assay2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1764899Volume of distribution at steady state in cynomolgus monkey at 10 mg/kg, iv after 30 mins by LC-MS/MS analysis
AID1440678Time at which plasma concentration greater than in vitro EBOV antiviral IC50 in rhesus monkey PBMC assessed as ((2R,3S,4R,5R)-5-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate levels a2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1898564Selectivity index, ratio of CC50 for cytotoxicity against human Huh-7 cells to EC50 for antiviral activity against Human coronavirus 229E infected in human MRC5 cells2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
AID1717762Antiviral activity against SARS-CoV expressing green fluorescent protein infected in human airway epithelial cells incubated for 48 hrs by RT-PCR method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1918733Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay2022Journal of natural products, 12-23, Volume: 85, Issue:12
Evaluating the
AID1717758Selectivity index, ratio of CC50 for human Huh-7 cells to EC50 for HCoV-OC43 infected in human Huh-7 cells2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1918725Cytotoxicity against human HCT-8 cells assessed as redcution in cell viability at 10 uM incubated for 96 hrs by PrestoBlue reagent based assay relative to control2022Journal of natural products, 12-23, Volume: 85, Issue:12
Evaluating the
AID1815331Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by coulter counter method2021European journal of medicinal chemistry, Dec-15, Volume: 226Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.
AID1440652Antiviral activity against Ebolavirus Kikwit infected in human HeLa cells assessed as reduction in viral glycoprotein levels preincubated with cells for 2 hrs followed by viral infection measured after 48 hrs by immunostaining based assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1877272Antiviral activity against Severe acute respiratory syndrome coronavirus 2 infected in African green monkey Vero E6 cells assessed as inhibition of viral cytopathic effect at 200 uM incubated for 72 hrs by CCK8 assay relative to control2022European journal of medicinal chemistry, Jan-05, Volume: 227Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2.
AID1764960Antiviral activity against RSV A2 infected in african green monkey assessed as reduction in nasal viral load at 10 mg/kg, iv administered 4 hrs prior to viral infection and daily upto 5 days post infection and measured every other day until day 15 by RT-q
AID1764941Drug metabolism in african green monkey assessed as 1-NTP metabolite concentration in lower bronchi at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1880957Antiviral activity against SARS-COV 2 infected in human Calu-3 cells assessed as inhibition of viral replication preincubated for 1 hr followed by viral infection and further incubated with compound for 24 hrs
AID1897959Cytotoxicity against african green monkey Vero E6 cells assessed as reduction in cell viability after 26 hrs by MTS assay2022Journal of medicinal chemistry, 12-22, Volume: 65, Issue:24
Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors.
AID1661023Cytotoxic activity in HAE cells2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment.
AID1918734Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by PrestoBlue reagent based assay2022Journal of natural products, 12-23, Volume: 85, Issue:12
Evaluating the
AID1764928Cmax in African green monkey at 10 mg/kg, iv after 30 mins by LC-MS/MS analysis
AID1772425Antiviral activity against HCoV-NL63 infected in LLC-MK2 cells assessed as reduction in viral replication treated 1 hr post infection and measured after 120 hrs post infection by MTS cell proliferation colorimetric assay2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.
AID1783421Antiviral activity against SARS-COV 2 infected in human Caco-2 cells2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1467740Antiviral activity against Ebolavirus H. sapiens-tc/COD/1995/Kikwit infected in rhesus monkey assessed as host survival at 10 mg/kg, iv administered as bolus dose2018Journal of medicinal chemistry, 03-22, Volume: 61, Issue:6
The ProTide Prodrug Technology: From the Concept to the Clinic.
AID1898548Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-glo luminescent cell viability assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
AID1898373Antiviral activity against SARS-COV 2 infected in human Caco-2 cells assessed as inhibition of viral replication after 48 hrs by qRT-PCR analysis2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.
AID1440698Antiviral activity against Ebolavirus infected in rhesus monkey assessed as survival rate at 10 mg/kg, iv administered daily starting from day 3 post infection for 12 days relative to control2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1815250Antiviral activity against SARS-CoV-2/NL/2020 infected in African green monkey Vero E6 cells assessed as inhibition of plaque formation measured after 3 days by Plaque reduction assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Indomethacin-based PROTACs as pan-coronavirus antiviral agents.
AID1918729Antiviral activity against SARS-CoV-2 infected in African green monkey Vero cells assessed as inhibition of viral growth incubated for 2 days by ELISA analysis2022Journal of natural products, 12-23, Volume: 85, Issue:12
Evaluating the
AID1717756Antiviral activity against wild type HCoV-OC43 infected in human Huh-7 cells preincubated for 1 hrs followed by overlaying with reduced-serum Medium and measured after 72 hrs ELISpot assay2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1764920Drug metabolism in HAE cells assessed as 1-NTP metabolite concentration at 1 uM over 48 hrs by LC-MS/MS analysis
AID1890671Antiviral activity against SARS-CoV-2 isolate USA-WA1/2020 infected in Calu-3 cells preincubated for 24 hrs followed by viral infection and measured after 48 hrs by Hoechst 33342 staining based microscopic method2022Journal of natural products, 03-25, Volume: 85, Issue:3
Marine Natural Products as Leads against SARS-CoV-2 Infection.
AID1785768Antiviral activity against SARS-CoV-2 C-Tan-nCoV Wuhan strain 01 virus infected in Hamster rat assessed as widening of bronchus at 25 mg/kg, inh administered for 3 days starting from 1 hr post infection and measured on day 4 by histopathological analysis
AID1764958AUCinfinity in cynomolgus monkey at 10 mg/kg, iv after 30 mins by LC-MS/MS analysis
AID1440653Antiviral activity against GFP-fused Ebolavirus infected in TERT-immortalized HMVEC assessed as reduction in viral replication preincubated with cells followed by viral infection measured after 3 to 4 days by fluorescence assay2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1764956Terminal half life in cynomolgus monkey at 10 mg/kg, iv after 30 mins by LC-MS/MS analysis
AID1811328Metabolic stability in human plasma assessed as drug degradation at 10 uM after 1 hr by LC-QTOF-MS analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1877262Antiviral activity against Severe acute respiratory syndrome coronavirus 2 infected in African green monkey Vero E6 cells assessed as inhibition of viral cytopathic effect incubated for 72 hrs by CCK8 assay2022European journal of medicinal chemistry, Jan-05, Volume: 227Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2.
AID1440689Drug uptake in cynomolgus monkey brain at 10 mg/kg, iv at 168 hrs post dose2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1766128Antiviral activity against SARS-CoV-2 isolate USA-WA1/2020 infected in Vero E6 cells assessed as reduction in virus induced cytopathic effect incubated for 72 hrs by alamar blue assay2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.
AID1440688Drug uptake in cynomolgus monkey brain at 10 mg/kg, iv at 4 hrs post dose2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1772422Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected nsp12 along with nsp14 and nsp102021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.
AID1764944Drug metabolism in african green monkey assessed as 1-NTP metabolite concentration in main stem bronchi at 10 mg/kg, iv measured after 24 hrs by LC-MS/MS analysis
AID1815330Cytotoxicity against African green monkey Vero cells assessed as effect on cell morphology by microscopic analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization.
AID1918726Antiviral activity against HCoV-OC43 infected in human HCT-8 cells assessed as inhibition of viral growth incubated for 4 days by ELISA analysis2022Journal of natural products, 12-23, Volume: 85, Issue:12
Evaluating the
AID1811329Metabolic stability in human plasma assessed as compound remaining at 10 uM after 2 hrs by LC-QTOF-MS analysis2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1682558Selectivity index, ratio of CC50 for African green monkey Vero cells infected with SARS-CoV-2 betaCoV/KOR/KCDC03/2020 to IC50 for SARS-CoV-2 betaCoV/KOR/KCDC03/20202021Bioorganic & medicinal chemistry letters, 01-01, Volume: 31Discovery of cyclic sulfonamide derivatives as potent inhibitors of SARS-CoV-2.
AID1440680Antiviral activity against Ebolavirus infected in rhesus monkey assessed as reduction in systemic viremia at 3 mg/kg, iv qd administered continuously starting from day 2 post infection for 12 days2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1898542Antiviral activity against Human coronavirus OC43 infected in human Huh-7 cells assessed as reduction in virus-induced cytopathic effect incubated for 7 days by Celltiter-Glo assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
AID1772418Inhibition of SARS-CoV-2 RdRp transfected in human HEK293T cells cotransfected with Cov-Gluc by Gaussia luciferase reporter gene method2021European journal of medicinal chemistry, Nov-05, Volume: 223Discovery and optimization of 2-((1H-indol-3-yl)thio)-N-benzyl-acetamides as novel SARS-CoV-2 RdRp inhibitors.
AID1785775Antiviral activity against SARS-CoV-2 C-Tan-nCoV Wuhan strain 01 virus infected in Hamster rat assessed as infiltration of lymphocytes at 5 mg/kg, inh administered for 3 days starting from 1 hr post infection and measured on day 4 by histopathological ana
AID1898549Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability incubated for 24 hrs by Celltiter-glo luminescent cell viability assay2022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and
AID1880958Antiviral activity against SARS-COV 2 infected in Vero 76 cells assessed as inhibition of viral replication preincubated for 1 hr followed by viral infection and further incubated with compound for 24 hrs
AID1783392Selectivity index, ratio of CC50 for human Caco-2 cells infected with SARS-COV-2 to IC50 of SARS-COV 2 infected in human Caco-2 cells2021European journal of medicinal chemistry, Nov-15, Volume: 224System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1764917Drug metabolism in human HEp-2 cells assessed as 1-NTP formation at 1 to 10 uM after 2 hrs by LC-MS/MS analysis
AID1877269Antiviral activity against Severe acute respiratory syndrome coronavirus 2 infected in African green monkey Vero E6 cells assessed as inhibition of viral cytopathic effect at 1.6 uM incubated for 72 hrs by CCK8 assay relative to control2022European journal of medicinal chemistry, Jan-05, Volume: 227Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2.
AID1764923Cmax in human at 75 mg, iv measured after 30 mins
AID1717750Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for 2019-nCoV Beta CoV/Wuhan/WIV04/2019 infected in African green monkey Vero E6 cells2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1893720Cytotoxicity against human A549 cells overexpressing ACE2 and TMPRSS2 incubated for 48 hrs by MTS assay
AID1764924Cmax in human at 75 mg, iv measured after 1 hr
AID1440686Drug uptake in cynomolgus monkey plasma at 10 mg/kg, iv at 4 hrs post dose2017Journal of medicinal chemistry, 03-09, Volume: 60, Issue:5
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses.
AID1764914Antiviral activity against RSV infected in NHBE cells after 3 days by ONE-Glo luciferase assay
AID1811334Antiviral activity against SARS-CoV-2 nCoV-2019 BetaCoV/Wuhan/WIV04/2019 infected in African green monkey VeroE6 cells incubated for 48 hrs by qRT-PCR method2021European journal of medicinal chemistry, Dec-15, Volume: 226Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus.
AID1774052Antiviral activity against SARS-CoV-2 JPN/TY/WK-251 infected in Vero E6 cells assessed as reduction in number of infected cells at 10 uM after 3 days by immunocytochemistry analysis2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.
AID1684807Cytotoxicity against African green monkey Vero cells assessed as alteration in cell morphology by microscopic analysis2021ACS medicinal chemistry letters, Jan-14, Volume: 12, Issue:1
Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
AID1815249Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 72 hrs by MTT assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Indomethacin-based PROTACs as pan-coronavirus antiviral agents.
AID1805295replicon assay from Article 10.1021/acsmedchemlett.1c00326: \\Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.\\2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.
AID1804171DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\2020Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
AID1804127No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\2021Medicinal research reviews, 01, Volume: 41, Issue:1
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID1805296infectious virus assay from Article 10.1021/acsmedchemlett.1c00326: \\Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.\\2021ACS medicinal chemistry letters, Aug-12, Volume: 12, Issue:8
Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,211)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's19 (1.57)24.3611
2020's1192 (98.43)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials52 (4.17%)5.53%
Reviews268 (21.51%)6.00%
Case Studies105 (8.43%)4.05%
Observational51 (4.09%)0.25%
Other770 (61.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]